Register for our free email digests:
Ablynx N.V.
http://www.ablynx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ablynx N.V.
Riding On Exosome Potential, Evox Eyes Unicorn Status
A financing round that was significantly oversubscribed by new and existing investors will help advance the Oxford-headquartered biotech's exosome therapeutics into the clinic and expand its technology platform.
Phase II Win For Merck KGaA/Avillion Psoriasis Drug May Be Too Late
The German major is looking for a partner to advance its IL-17A/IL-17F nanobody sonelokinab for psoriasis but the search could be tricky given the strength of Novartis's Cosentyx and Eli Lilly's Taltz, while UCB's IL-17A and IL-17F inhibitor bimekizumab is likely to be approved soon.
ExeVir Bio Looks To Llamas To Tackle Coronavirus Crisis
UCB and Fund+ are supporting a spin out from the renowned VIB research institute and ExeVir Bio CEO Torsten Mummenbrauer told Scrip that the firm's llama antibodies should be in the clinic for COVID-19 possibly by November.
Reapplix ‘Focused Exclusively’ On US Wound Patch Launch After Securing Reimbursement
Reapplix’s CEO tells Medtech Insight the Danish group now has the funds to launch its biological wound healing patch in the US for treating patients with diabetic foot ulcers.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Ablynx NV